SlideShare a Scribd company logo
1 of 21
UNDERSTANDING THE NEW
OPIOID RULES
BY:
RENALDO P. DeFRANK, JR.
LEVASSEUR & DEFRANK, P.C.
November 18, 2015
WHAT ARE OPIOIDS?
• Opioids are medications
that are prescribed to
relieve acute/chronic
pain
• Most opioids come in pill
or tablet form and can be
taken by mouth, but they
can also be prescribed in
patch form
• Common opioids being
prescribed are
hydrocodone (e.g.
Vicodin), oxycodone (e.g.
Oxycontin, Percocet) and
morphine (e.g. Kadian)
INTRODUCTION OF OPIOIDS TO THE
INJURED WORKER
• Treatment is provided to an injured worker
after an injury
• Physician determines that the degree of pain
merits the use of opioids
• The injured worker begins taking the
prescribed medication
• The path of opioid use begins!
CHRONIC PAIN
• Chronic pain exists beyond an
expected time for healing. It is
a persistent pain state not
associated with malignancy or
acute pain caused by trauma,
surgery infection or other
factors. However, these and
other pain sources, such as
sprains or twists, may
symptomatically persist to
become chronic benign pain.
The intensity will vary from
mild to severe disabling pain
that may significantly reduce
quality of life
OPIOID CONCERNS
• Dependence
• Addiction
• Abuse
– Over medicating
– Overdosing
– Selling the opioids to make $$$
• High medical costs
• Legal exposure
• Medicare!!!
THE OPIOID MOVEMENT
• In October 2014, the FDA reclassified combination drugs with
hydrocodone as Schedule II drugs (HIGH POTENTIAL FOR ABUSE!!!)
• Methadone and Oxycodone are also Schedule II drugs
• This requires patients to see their doctors to obtain new
prescriptions, as opposed to obtaining refills without an office visit
• The reclassification limits somewhat the ease of access to opioids
AMENDMENTS TO THE WORKERS’
COMPENSATION RULES
• The Michigan Workers’ Compensation Agency (WCA) amended the
Workers’ Compensation Health Care Services rules and fee
schedule, effective December 26, 2014
• The amendments were put in place to address the problem of long-
term use of opioids by injured workers and help reduce medical
costs for the State’s job providers
• Limit potential addiction problems for injured workers, to keep
them healthy and get them back to work
• Rule 1008. (1) For purposes of these rules, chronic pain is
pain unrelated to cancer or is incident to surgery and
that persists beyond the period of expected healing after
an acute injury episode. It is pain that persists beyond 90
days following the onset of the pain. The payer shall
reimburse for opioids used in the treatment of chronic
pain resulting from work-related conditions.
• (2) This rule is applicable to opioid treatment of chronic
pain for the following: (a) Injury dates on or after June
26, 2015. (b) Beginning December 26, 2015, all other
injury dates.
R 418.101008 Reimbursement for opioid
treatment for chronic, non-cancer pain
R 418.101008a Required documentation for
reimbursement of treatment for chronic, non-cancer
pain with opioids.
• Rule 1008a. (1) In order to receive reimbursement for opioid
treatment beyond 90 days, the physician seeking reimbursement
shall submit a written report to the payer not later than 90 days
after the initial opioid prescription fill for chronic pain and every 90
days thereafter. The written report shall include all of the following:
• (a) A review and analysis of the relevant prior medical history,
including any consultations that have been obtained, and a review
of data received from an automated prescription drug monitoring
program in the treating jurisdiction, such as the Michigan
Automated Prescription System (MAPS), for identification of past
history of narcotic use and any concurrent prescriptions.
• (b) A summary of conservative care rendered to the worker that
focused on increased function and return to work.
• (c) A statement on why prior or alternative conservative measures
were ineffective or contraindicated.
• (d) A statement that the attending physician has considered the
results obtained from appropriate industry accepted screening tools
to detect factors that may significantly increase the risk of abuse or
adverse outcomes including a history of alcohol or other substance
abuse.
• (e) A treatment plan which includes all of the following: (i) Overall
treatment goals and functional progress. (ii) Periodic urine drug
screens. (iii) A conscientious effort to reduce pain through the use
of non-opioid medications, alternative non-pharmaceutical
strategies, or both. (iv) Consideration of weaning the injured worker
from opioid use.
• (f) An opioid treatment agreement that has been signed by the
worker and the attending physician. This agreement shall be
reviewed, updated, and renewed every 6 months. The opioid
treatment agreement shall outline the risks and benefits of opioid
use, the conditions under which opioids will be prescribed, and the
responsibilities of the prescribing physician and the worker.
• (2) The provider may bill the additional services required for
compliance with these rules utilizing CPT procedure code 99215 for
the initial 90 day report and all subsequent follow-up reports at 90-
day intervals.
• (3) Providers may bill $25.00 utilizing code MPS01 for accessing
MAPS or other automated prescription drug monitoring program in
the treating jurisdiction.
R 418.101008b Denial of reimbursement for
prescribing and dispensing opioid medications used to
treat chronic, non-cancer pain.
• Rule 1008b. Reimbursement for prescribing and dispensing opioid
medications may be denied, pursuant to the act. Denial of
reimbursement may occur if the physician reporting and treatment
plan requirements as stated in R 418.101008a are not met. Denial
of reimbursement shall occur only after a reasonable period of
time is provided for the weaning of the injured worker from the
opioid medications, and alternative means of pain management
have been offered.
WHAT DOES ALL OF THIS MEAN?
• Limits the ease to which
opioids are prescribed
• Extra hoops for physicians
to jump through in order
to get paid
• Detailed reports to
support the need for
opioid treatment
• Potential to curb the
prescription of opioids in
the first place
MAPS!
IMPACT ON WORK COMP CLAIMS
• Opioids are the most common
treatment for chronic pain
– A 2013 study found that 30%
of physician visits for back
and/or neck pain resulted in a
prescription for opioids
– As many as 90% of pain
management patients in the
U.S. receive opioids for
chronic pain
– 50% of patients who take
opioids daily for 90 days are
still taking them daily 5 years
later
LEADING PRESCRIBERS
WHAT DO THESE STATS MEAN?
• The stats show that family physicians, as opposed to pain
management specialists, are prescribing most of the opioids being
used today
• Once an injured worker goes down the opioid route, the odds of
long-term opioid use is significant
• Potential problems are on the horizon
WHY SHOULD YOU CARE ABOUT
OPIOID USE?
• Detrimental to the workforce
– Could prevent the injured worker from ever getting back to
work
• Cost of opioids is high
– Future medical treatment costs will be significant
– Need for periodic drug testing
– Potential need for a drug weaning program
– Increases the exposure of a given workers’ compensation claim
– Could lead to a large MSA amount and be an impediment to
settlement
HOW TO AVOID OPIOID PROBLEMS
• Be sure to direct medical care for the first 28 days after an injury
occurs
– Could prevent the opioid cycle from starting
• If/when opioids are being discussed as part of a treatment plan,
consider a second opinion (e.g. IME)
• Consider the use of a Nurse Case Manager (NCM) to oversee the
treatment plan, once opioids are prescribed
– Discuss alternatives to opioid treatment
– Monitor the reports from the physicians in support of the
continued use of opioids
– Once opioids are being used, determine the appropriate plan to
wean the injured worker off of the opioids
• Contact an attorney to discuss the claim
QUESTIONS?
Renaldo P. DeFrank, Jr.
LeVasseur & DeFrank, P.C.
24725 W. 12 Mile Rd., Ste 230
Southfield, MI 48034
Office: 248-356-8600
Cell: 248-207-6365
www.levasseurlaw.com
rdefrank@levasseurlaw.com

More Related Content

What's hot

Presentation: A journey to better medicine labels - an update on TGO 92
Presentation: A journey to better medicine labels - an update on TGO 92Presentation: A journey to better medicine labels - an update on TGO 92
Presentation: A journey to better medicine labels - an update on TGO 92TGA Australia
 
International society of pharmacovigilance (IsOP) training course: Early acce...
International society of pharmacovigilance (IsOP) training course: Early acce...International society of pharmacovigilance (IsOP) training course: Early acce...
International society of pharmacovigilance (IsOP) training course: Early acce...TGA Australia
 
Pharmacovigilance in Australia
Pharmacovigilance in AustraliaPharmacovigilance in Australia
Pharmacovigilance in AustraliaSaeeda Hasan
 
Pharmacovigilance full information
Pharmacovigilance full informationPharmacovigilance full information
Pharmacovigilance full informationRavindra Kumar
 
TGA presentation: Provisional approval pathway for prescription medicines
TGA presentation: Provisional approval pathway for prescription medicinesTGA presentation: Provisional approval pathway for prescription medicines
TGA presentation: Provisional approval pathway for prescription medicinesTGA Australia
 
Pharmacovigilance overview
Pharmacovigilance overviewPharmacovigilance overview
Pharmacovigilance overviewAcri India
 
Pharmacovigilance & pv pi
Pharmacovigilance & pv piPharmacovigilance & pv pi
Pharmacovigilance & pv piNikhilNaikwadi3
 
Current Pharmacovigilance Practice And Improving Methods
Current Pharmacovigilance Practice And Improving MethodsCurrent Pharmacovigilance Practice And Improving Methods
Current Pharmacovigilance Practice And Improving Methodsavinashkhairnar
 
TGA Presentation: TGA Approval Pathways
TGA Presentation: TGA Approval PathwaysTGA Presentation: TGA Approval Pathways
TGA Presentation: TGA Approval PathwaysTGA Australia
 
importance of pharmcovigilance
importance of pharmcovigilanceimportance of pharmcovigilance
importance of pharmcovigilancesiddemsetty nikhil
 
History n progress of pv
History n progress of pvHistory n progress of pv
History n progress of pvRamavath Aruna
 
Pharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsPharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsTGA Australia
 
Presentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access BranchPresentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
 
Pharmacovigilance by khaga
Pharmacovigilance by khagaPharmacovigilance by khaga
Pharmacovigilance by khagaKhadga Raj
 
NICE -the-safe-use-and-management-of-controlled-drugs3
NICE -the-safe-use-and-management-of-controlled-drugs3NICE -the-safe-use-and-management-of-controlled-drugs3
NICE -the-safe-use-and-management-of-controlled-drugs3Denis Moran
 
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...TGA Australia
 
Better medicine labels: New requirements under TGOs 91 and 92
Better medicine labels: New requirements under TGOs 91 and 92Better medicine labels: New requirements under TGOs 91 and 92
Better medicine labels: New requirements under TGOs 91 and 92TGA Australia
 
Signifcance of pharmacovigilance & risk management plan
Signifcance of pharmacovigilance & risk management planSignifcance of pharmacovigilance & risk management plan
Signifcance of pharmacovigilance & risk management planAnsuman Parida
 
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTIONROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTIONAnindya Banerjee
 

What's hot (20)

Presentation: A journey to better medicine labels - an update on TGO 92
Presentation: A journey to better medicine labels - an update on TGO 92Presentation: A journey to better medicine labels - an update on TGO 92
Presentation: A journey to better medicine labels - an update on TGO 92
 
International society of pharmacovigilance (IsOP) training course: Early acce...
International society of pharmacovigilance (IsOP) training course: Early acce...International society of pharmacovigilance (IsOP) training course: Early acce...
International society of pharmacovigilance (IsOP) training course: Early acce...
 
Pharmacovigilance in Australia
Pharmacovigilance in AustraliaPharmacovigilance in Australia
Pharmacovigilance in Australia
 
Pharmacovigilance full information
Pharmacovigilance full informationPharmacovigilance full information
Pharmacovigilance full information
 
TGA presentation: Provisional approval pathway for prescription medicines
TGA presentation: Provisional approval pathway for prescription medicinesTGA presentation: Provisional approval pathway for prescription medicines
TGA presentation: Provisional approval pathway for prescription medicines
 
Pharmacovigilance overview
Pharmacovigilance overviewPharmacovigilance overview
Pharmacovigilance overview
 
Pharmacovigilance & pv pi
Pharmacovigilance & pv piPharmacovigilance & pv pi
Pharmacovigilance & pv pi
 
Current Pharmacovigilance Practice And Improving Methods
Current Pharmacovigilance Practice And Improving MethodsCurrent Pharmacovigilance Practice And Improving Methods
Current Pharmacovigilance Practice And Improving Methods
 
TGA Presentation: TGA Approval Pathways
TGA Presentation: TGA Approval PathwaysTGA Presentation: TGA Approval Pathways
TGA Presentation: TGA Approval Pathways
 
importance of pharmcovigilance
importance of pharmcovigilanceimportance of pharmcovigilance
importance of pharmcovigilance
 
History n progress of pv
History n progress of pvHistory n progress of pv
History n progress of pv
 
Pharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsPharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirements
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Presentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access BranchPresentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access Branch
 
Pharmacovigilance by khaga
Pharmacovigilance by khagaPharmacovigilance by khaga
Pharmacovigilance by khaga
 
NICE -the-safe-use-and-management-of-controlled-drugs3
NICE -the-safe-use-and-management-of-controlled-drugs3NICE -the-safe-use-and-management-of-controlled-drugs3
NICE -the-safe-use-and-management-of-controlled-drugs3
 
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...
 
Better medicine labels: New requirements under TGOs 91 and 92
Better medicine labels: New requirements under TGOs 91 and 92Better medicine labels: New requirements under TGOs 91 and 92
Better medicine labels: New requirements under TGOs 91 and 92
 
Signifcance of pharmacovigilance & risk management plan
Signifcance of pharmacovigilance & risk management planSignifcance of pharmacovigilance & risk management plan
Signifcance of pharmacovigilance & risk management plan
 
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTIONROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
 

Similar to UNDERSTANDING THE NEW OPIOID RULES

Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...
Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...
Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...BU School of Medicine
 
webmm slideshow.ppt
webmm slideshow.pptwebmm slideshow.ppt
webmm slideshow.pptssuser579a28
 
Rx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notesRx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notesOPUNITE
 
Kathryn Mueller
Kathryn MuellerKathryn Mueller
Kathryn MuellerOPUNITE
 
Antimicrobial stewardship CME 04-03-19
Antimicrobial stewardship CME 04-03-19Antimicrobial stewardship CME 04-03-19
Antimicrobial stewardship CME 04-03-19Tahseen Siddiqui
 
Cost saving strategies_updated
Cost saving strategies_updatedCost saving strategies_updated
Cost saving strategies_updatedOPUNITE
 
Rx15 tpp wed_1115_2_fisher_3skinner
Rx15 tpp wed_1115_2_fisher_3skinnerRx15 tpp wed_1115_2_fisher_3skinner
Rx15 tpp wed_1115_2_fisher_3skinnerOPUNITE
 
Challenges in Managing Cancer Pain: The Role of the Oncology Pharmacist
Challenges in Managing Cancer Pain: The Role of the Oncology PharmacistChallenges in Managing Cancer Pain: The Role of the Oncology Pharmacist
Challenges in Managing Cancer Pain: The Role of the Oncology Pharmacistflasco_org
 
Medicines, Legislations and Optometrists
Medicines, Legislations and Optometrists Medicines, Legislations and Optometrists
Medicines, Legislations and Optometrists Dr Htet
 
PFP The Pharmacist Role.pptx
PFP The Pharmacist Role.pptxPFP The Pharmacist Role.pptx
PFP The Pharmacist Role.pptxIngridVeronica3
 
pfpthepharmacistrole-221219062755-664bbb99.pptx
pfpthepharmacistrole-221219062755-664bbb99.pptxpfpthepharmacistrole-221219062755-664bbb99.pptx
pfpthepharmacistrole-221219062755-664bbb99.pptxMohammedAlaa62
 
Prescription Medicines MMDR Reforms
Prescription Medicines MMDR ReformsPrescription Medicines MMDR Reforms
Prescription Medicines MMDR ReformsTGA Australia
 
guidelines factsheet cdc pocp
guidelines factsheet cdc pocpguidelines factsheet cdc pocp
guidelines factsheet cdc pocpfabiointerlandi
 
Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?RIAPA
 
Presentation: Prescription Medicines Reforms
Presentation: Prescription Medicines ReformsPresentation: Prescription Medicines Reforms
Presentation: Prescription Medicines ReformsTGA Australia
 

Similar to UNDERSTANDING THE NEW OPIOID RULES (20)

The Opioid Epidemic - N Elkins
The Opioid Epidemic - N ElkinsThe Opioid Epidemic - N Elkins
The Opioid Epidemic - N Elkins
 
Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...
Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...
Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...
 
webmm slideshow.ppt
webmm slideshow.pptwebmm slideshow.ppt
webmm slideshow.ppt
 
Rx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notesRx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notes
 
TMB pain management rules
TMB pain management rulesTMB pain management rules
TMB pain management rules
 
Kathryn Mueller
Kathryn MuellerKathryn Mueller
Kathryn Mueller
 
Antimicrobial stewardship CME 04-03-19
Antimicrobial stewardship CME 04-03-19Antimicrobial stewardship CME 04-03-19
Antimicrobial stewardship CME 04-03-19
 
CDC_Guidelines
CDC_GuidelinesCDC_Guidelines
CDC_Guidelines
 
Cost saving strategies_updated
Cost saving strategies_updatedCost saving strategies_updated
Cost saving strategies_updated
 
Rx15 tpp wed_1115_2_fisher_3skinner
Rx15 tpp wed_1115_2_fisher_3skinnerRx15 tpp wed_1115_2_fisher_3skinner
Rx15 tpp wed_1115_2_fisher_3skinner
 
Challenges in Managing Cancer Pain: The Role of the Oncology Pharmacist
Challenges in Managing Cancer Pain: The Role of the Oncology PharmacistChallenges in Managing Cancer Pain: The Role of the Oncology Pharmacist
Challenges in Managing Cancer Pain: The Role of the Oncology Pharmacist
 
Medicines, Legislations and Optometrists
Medicines, Legislations and Optometrists Medicines, Legislations and Optometrists
Medicines, Legislations and Optometrists
 
PFP The Pharmacist Role.pptx
PFP The Pharmacist Role.pptxPFP The Pharmacist Role.pptx
PFP The Pharmacist Role.pptx
 
pfpthepharmacistrole-221219062755-664bbb99.pptx
pfpthepharmacistrole-221219062755-664bbb99.pptxpfpthepharmacistrole-221219062755-664bbb99.pptx
pfpthepharmacistrole-221219062755-664bbb99.pptx
 
Prescription Medicines MMDR Reforms
Prescription Medicines MMDR ReformsPrescription Medicines MMDR Reforms
Prescription Medicines MMDR Reforms
 
guidelines factsheet cdc pocp
guidelines factsheet cdc pocpguidelines factsheet cdc pocp
guidelines factsheet cdc pocp
 
Regulatory Procedures
Regulatory ProceduresRegulatory Procedures
Regulatory Procedures
 
Webinar: Oncology Care Model - Introduction
Webinar: Oncology Care Model - IntroductionWebinar: Oncology Care Model - Introduction
Webinar: Oncology Care Model - Introduction
 
Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?
 
Presentation: Prescription Medicines Reforms
Presentation: Prescription Medicines ReformsPresentation: Prescription Medicines Reforms
Presentation: Prescription Medicines Reforms
 

Recently uploaded

The Active Management Value Ratio: The New Science of Benchmarking Investment...
The Active Management Value Ratio: The New Science of Benchmarking Investment...The Active Management Value Ratio: The New Science of Benchmarking Investment...
The Active Management Value Ratio: The New Science of Benchmarking Investment...James Watkins, III JD CFP®
 
一比一原版利兹大学毕业证学位证书
一比一原版利兹大学毕业证学位证书一比一原版利兹大学毕业证学位证书
一比一原版利兹大学毕业证学位证书E LSS
 
如何办理普利茅斯大学毕业证(本硕)Plymouth学位证书
如何办理普利茅斯大学毕业证(本硕)Plymouth学位证书如何办理普利茅斯大学毕业证(本硕)Plymouth学位证书
如何办理普利茅斯大学毕业证(本硕)Plymouth学位证书Fir L
 
如何办理(Lincoln文凭证书)林肯大学毕业证学位证书
如何办理(Lincoln文凭证书)林肯大学毕业证学位证书如何办理(Lincoln文凭证书)林肯大学毕业证学位证书
如何办理(Lincoln文凭证书)林肯大学毕业证学位证书Fs Las
 
Offences against property (TRESPASS, BREAKING
Offences against property (TRESPASS, BREAKINGOffences against property (TRESPASS, BREAKING
Offences against property (TRESPASS, BREAKINGPRAKHARGUPTA419620
 
Model Call Girl in Haqiqat Nagar Delhi reach out to us at 🔝8264348440🔝
Model Call Girl in Haqiqat Nagar Delhi reach out to us at 🔝8264348440🔝Model Call Girl in Haqiqat Nagar Delhi reach out to us at 🔝8264348440🔝
Model Call Girl in Haqiqat Nagar Delhi reach out to us at 🔝8264348440🔝soniya singh
 
Essentials of a Valid Transfer.pptxmmmmmm
Essentials of a Valid Transfer.pptxmmmmmmEssentials of a Valid Transfer.pptxmmmmmm
Essentials of a Valid Transfer.pptxmmmmmm2020000445musaib
 
如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书
如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书
如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书Fir L
 
Indemnity Guarantee Section 124 125 and 126
Indemnity Guarantee Section 124 125 and 126Indemnity Guarantee Section 124 125 and 126
Indemnity Guarantee Section 124 125 and 126Oishi8
 
如何办理(USF文凭证书)美国旧金山大学毕业证学位证书
如何办理(USF文凭证书)美国旧金山大学毕业证学位证书如何办理(USF文凭证书)美国旧金山大学毕业证学位证书
如何办理(USF文凭证书)美国旧金山大学毕业证学位证书Fs Las
 
如何办理(UoM毕业证书)曼彻斯特大学毕业证学位证书
如何办理(UoM毕业证书)曼彻斯特大学毕业证学位证书如何办理(UoM毕业证书)曼彻斯特大学毕业证学位证书
如何办理(UoM毕业证书)曼彻斯特大学毕业证学位证书srst S
 
一比一原版牛津布鲁克斯大学毕业证学位证书
一比一原版牛津布鲁克斯大学毕业证学位证书一比一原版牛津布鲁克斯大学毕业证学位证书
一比一原版牛津布鲁克斯大学毕业证学位证书E LSS
 
如何办理(KPU毕业证书)加拿大昆特兰理工大学毕业证学位证书
 如何办理(KPU毕业证书)加拿大昆特兰理工大学毕业证学位证书 如何办理(KPU毕业证书)加拿大昆特兰理工大学毕业证学位证书
如何办理(KPU毕业证书)加拿大昆特兰理工大学毕业证学位证书Fir sss
 
Introduction to Corruption, definition, types, impact and conclusion
Introduction to Corruption, definition, types, impact and conclusionIntroduction to Corruption, definition, types, impact and conclusion
Introduction to Corruption, definition, types, impact and conclusionAnuragMishra811030
 
Ricky French: Championing Truth and Change in Midlothian
Ricky French: Championing Truth and Change in MidlothianRicky French: Championing Truth and Change in Midlothian
Ricky French: Championing Truth and Change in MidlothianRicky French
 
Andrea Hill Featured in Canadian Lawyer as SkyLaw Recognized as a Top Boutique
Andrea Hill Featured in Canadian Lawyer as SkyLaw Recognized as a Top BoutiqueAndrea Hill Featured in Canadian Lawyer as SkyLaw Recognized as a Top Boutique
Andrea Hill Featured in Canadian Lawyer as SkyLaw Recognized as a Top BoutiqueSkyLaw Professional Corporation
 
Cleades Robinson's Commitment to Service
Cleades Robinson's Commitment to ServiceCleades Robinson's Commitment to Service
Cleades Robinson's Commitment to ServiceCleades Robinson
 
如何办理密德萨斯大学毕业证(本硕)Middlesex学位证书
如何办理密德萨斯大学毕业证(本硕)Middlesex学位证书如何办理密德萨斯大学毕业证(本硕)Middlesex学位证书
如何办理密德萨斯大学毕业证(本硕)Middlesex学位证书FS LS
 
THE FACTORIES ACT,1948 (2).pptx labour
THE FACTORIES ACT,1948 (2).pptx   labourTHE FACTORIES ACT,1948 (2).pptx   labour
THE FACTORIES ACT,1948 (2).pptx labourBhavikaGholap1
 

Recently uploaded (20)

The Active Management Value Ratio: The New Science of Benchmarking Investment...
The Active Management Value Ratio: The New Science of Benchmarking Investment...The Active Management Value Ratio: The New Science of Benchmarking Investment...
The Active Management Value Ratio: The New Science of Benchmarking Investment...
 
一比一原版利兹大学毕业证学位证书
一比一原版利兹大学毕业证学位证书一比一原版利兹大学毕业证学位证书
一比一原版利兹大学毕业证学位证书
 
如何办理普利茅斯大学毕业证(本硕)Plymouth学位证书
如何办理普利茅斯大学毕业证(本硕)Plymouth学位证书如何办理普利茅斯大学毕业证(本硕)Plymouth学位证书
如何办理普利茅斯大学毕业证(本硕)Plymouth学位证书
 
如何办理(Lincoln文凭证书)林肯大学毕业证学位证书
如何办理(Lincoln文凭证书)林肯大学毕业证学位证书如何办理(Lincoln文凭证书)林肯大学毕业证学位证书
如何办理(Lincoln文凭证书)林肯大学毕业证学位证书
 
Offences against property (TRESPASS, BREAKING
Offences against property (TRESPASS, BREAKINGOffences against property (TRESPASS, BREAKING
Offences against property (TRESPASS, BREAKING
 
Model Call Girl in Haqiqat Nagar Delhi reach out to us at 🔝8264348440🔝
Model Call Girl in Haqiqat Nagar Delhi reach out to us at 🔝8264348440🔝Model Call Girl in Haqiqat Nagar Delhi reach out to us at 🔝8264348440🔝
Model Call Girl in Haqiqat Nagar Delhi reach out to us at 🔝8264348440🔝
 
Essentials of a Valid Transfer.pptxmmmmmm
Essentials of a Valid Transfer.pptxmmmmmmEssentials of a Valid Transfer.pptxmmmmmm
Essentials of a Valid Transfer.pptxmmmmmm
 
如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书
如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书
如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书
 
Sensual Moments: +91 9999965857 Independent Call Girls Vasundhara Delhi {{ Mo...
Sensual Moments: +91 9999965857 Independent Call Girls Vasundhara Delhi {{ Mo...Sensual Moments: +91 9999965857 Independent Call Girls Vasundhara Delhi {{ Mo...
Sensual Moments: +91 9999965857 Independent Call Girls Vasundhara Delhi {{ Mo...
 
Indemnity Guarantee Section 124 125 and 126
Indemnity Guarantee Section 124 125 and 126Indemnity Guarantee Section 124 125 and 126
Indemnity Guarantee Section 124 125 and 126
 
如何办理(USF文凭证书)美国旧金山大学毕业证学位证书
如何办理(USF文凭证书)美国旧金山大学毕业证学位证书如何办理(USF文凭证书)美国旧金山大学毕业证学位证书
如何办理(USF文凭证书)美国旧金山大学毕业证学位证书
 
如何办理(UoM毕业证书)曼彻斯特大学毕业证学位证书
如何办理(UoM毕业证书)曼彻斯特大学毕业证学位证书如何办理(UoM毕业证书)曼彻斯特大学毕业证学位证书
如何办理(UoM毕业证书)曼彻斯特大学毕业证学位证书
 
一比一原版牛津布鲁克斯大学毕业证学位证书
一比一原版牛津布鲁克斯大学毕业证学位证书一比一原版牛津布鲁克斯大学毕业证学位证书
一比一原版牛津布鲁克斯大学毕业证学位证书
 
如何办理(KPU毕业证书)加拿大昆特兰理工大学毕业证学位证书
 如何办理(KPU毕业证书)加拿大昆特兰理工大学毕业证学位证书 如何办理(KPU毕业证书)加拿大昆特兰理工大学毕业证学位证书
如何办理(KPU毕业证书)加拿大昆特兰理工大学毕业证学位证书
 
Introduction to Corruption, definition, types, impact and conclusion
Introduction to Corruption, definition, types, impact and conclusionIntroduction to Corruption, definition, types, impact and conclusion
Introduction to Corruption, definition, types, impact and conclusion
 
Ricky French: Championing Truth and Change in Midlothian
Ricky French: Championing Truth and Change in MidlothianRicky French: Championing Truth and Change in Midlothian
Ricky French: Championing Truth and Change in Midlothian
 
Andrea Hill Featured in Canadian Lawyer as SkyLaw Recognized as a Top Boutique
Andrea Hill Featured in Canadian Lawyer as SkyLaw Recognized as a Top BoutiqueAndrea Hill Featured in Canadian Lawyer as SkyLaw Recognized as a Top Boutique
Andrea Hill Featured in Canadian Lawyer as SkyLaw Recognized as a Top Boutique
 
Cleades Robinson's Commitment to Service
Cleades Robinson's Commitment to ServiceCleades Robinson's Commitment to Service
Cleades Robinson's Commitment to Service
 
如何办理密德萨斯大学毕业证(本硕)Middlesex学位证书
如何办理密德萨斯大学毕业证(本硕)Middlesex学位证书如何办理密德萨斯大学毕业证(本硕)Middlesex学位证书
如何办理密德萨斯大学毕业证(本硕)Middlesex学位证书
 
THE FACTORIES ACT,1948 (2).pptx labour
THE FACTORIES ACT,1948 (2).pptx   labourTHE FACTORIES ACT,1948 (2).pptx   labour
THE FACTORIES ACT,1948 (2).pptx labour
 

UNDERSTANDING THE NEW OPIOID RULES

  • 1. UNDERSTANDING THE NEW OPIOID RULES BY: RENALDO P. DeFRANK, JR. LEVASSEUR & DEFRANK, P.C. November 18, 2015
  • 2. WHAT ARE OPIOIDS? • Opioids are medications that are prescribed to relieve acute/chronic pain • Most opioids come in pill or tablet form and can be taken by mouth, but they can also be prescribed in patch form • Common opioids being prescribed are hydrocodone (e.g. Vicodin), oxycodone (e.g. Oxycontin, Percocet) and morphine (e.g. Kadian)
  • 3.
  • 4. INTRODUCTION OF OPIOIDS TO THE INJURED WORKER • Treatment is provided to an injured worker after an injury • Physician determines that the degree of pain merits the use of opioids • The injured worker begins taking the prescribed medication • The path of opioid use begins!
  • 5. CHRONIC PAIN • Chronic pain exists beyond an expected time for healing. It is a persistent pain state not associated with malignancy or acute pain caused by trauma, surgery infection or other factors. However, these and other pain sources, such as sprains or twists, may symptomatically persist to become chronic benign pain. The intensity will vary from mild to severe disabling pain that may significantly reduce quality of life
  • 6. OPIOID CONCERNS • Dependence • Addiction • Abuse – Over medicating – Overdosing – Selling the opioids to make $$$ • High medical costs • Legal exposure • Medicare!!!
  • 7. THE OPIOID MOVEMENT • In October 2014, the FDA reclassified combination drugs with hydrocodone as Schedule II drugs (HIGH POTENTIAL FOR ABUSE!!!) • Methadone and Oxycodone are also Schedule II drugs • This requires patients to see their doctors to obtain new prescriptions, as opposed to obtaining refills without an office visit • The reclassification limits somewhat the ease of access to opioids
  • 8. AMENDMENTS TO THE WORKERS’ COMPENSATION RULES • The Michigan Workers’ Compensation Agency (WCA) amended the Workers’ Compensation Health Care Services rules and fee schedule, effective December 26, 2014 • The amendments were put in place to address the problem of long- term use of opioids by injured workers and help reduce medical costs for the State’s job providers • Limit potential addiction problems for injured workers, to keep them healthy and get them back to work
  • 9. • Rule 1008. (1) For purposes of these rules, chronic pain is pain unrelated to cancer or is incident to surgery and that persists beyond the period of expected healing after an acute injury episode. It is pain that persists beyond 90 days following the onset of the pain. The payer shall reimburse for opioids used in the treatment of chronic pain resulting from work-related conditions. • (2) This rule is applicable to opioid treatment of chronic pain for the following: (a) Injury dates on or after June 26, 2015. (b) Beginning December 26, 2015, all other injury dates. R 418.101008 Reimbursement for opioid treatment for chronic, non-cancer pain
  • 10. R 418.101008a Required documentation for reimbursement of treatment for chronic, non-cancer pain with opioids. • Rule 1008a. (1) In order to receive reimbursement for opioid treatment beyond 90 days, the physician seeking reimbursement shall submit a written report to the payer not later than 90 days after the initial opioid prescription fill for chronic pain and every 90 days thereafter. The written report shall include all of the following: • (a) A review and analysis of the relevant prior medical history, including any consultations that have been obtained, and a review of data received from an automated prescription drug monitoring program in the treating jurisdiction, such as the Michigan Automated Prescription System (MAPS), for identification of past history of narcotic use and any concurrent prescriptions. • (b) A summary of conservative care rendered to the worker that focused on increased function and return to work. • (c) A statement on why prior or alternative conservative measures were ineffective or contraindicated.
  • 11. • (d) A statement that the attending physician has considered the results obtained from appropriate industry accepted screening tools to detect factors that may significantly increase the risk of abuse or adverse outcomes including a history of alcohol or other substance abuse. • (e) A treatment plan which includes all of the following: (i) Overall treatment goals and functional progress. (ii) Periodic urine drug screens. (iii) A conscientious effort to reduce pain through the use of non-opioid medications, alternative non-pharmaceutical strategies, or both. (iv) Consideration of weaning the injured worker from opioid use. • (f) An opioid treatment agreement that has been signed by the worker and the attending physician. This agreement shall be reviewed, updated, and renewed every 6 months. The opioid treatment agreement shall outline the risks and benefits of opioid use, the conditions under which opioids will be prescribed, and the responsibilities of the prescribing physician and the worker.
  • 12. • (2) The provider may bill the additional services required for compliance with these rules utilizing CPT procedure code 99215 for the initial 90 day report and all subsequent follow-up reports at 90- day intervals. • (3) Providers may bill $25.00 utilizing code MPS01 for accessing MAPS or other automated prescription drug monitoring program in the treating jurisdiction.
  • 13. R 418.101008b Denial of reimbursement for prescribing and dispensing opioid medications used to treat chronic, non-cancer pain. • Rule 1008b. Reimbursement for prescribing and dispensing opioid medications may be denied, pursuant to the act. Denial of reimbursement may occur if the physician reporting and treatment plan requirements as stated in R 418.101008a are not met. Denial of reimbursement shall occur only after a reasonable period of time is provided for the weaning of the injured worker from the opioid medications, and alternative means of pain management have been offered.
  • 14. WHAT DOES ALL OF THIS MEAN? • Limits the ease to which opioids are prescribed • Extra hoops for physicians to jump through in order to get paid • Detailed reports to support the need for opioid treatment • Potential to curb the prescription of opioids in the first place
  • 15. MAPS!
  • 16. IMPACT ON WORK COMP CLAIMS • Opioids are the most common treatment for chronic pain – A 2013 study found that 30% of physician visits for back and/or neck pain resulted in a prescription for opioids – As many as 90% of pain management patients in the U.S. receive opioids for chronic pain – 50% of patients who take opioids daily for 90 days are still taking them daily 5 years later
  • 18. WHAT DO THESE STATS MEAN? • The stats show that family physicians, as opposed to pain management specialists, are prescribing most of the opioids being used today • Once an injured worker goes down the opioid route, the odds of long-term opioid use is significant • Potential problems are on the horizon
  • 19. WHY SHOULD YOU CARE ABOUT OPIOID USE? • Detrimental to the workforce – Could prevent the injured worker from ever getting back to work • Cost of opioids is high – Future medical treatment costs will be significant – Need for periodic drug testing – Potential need for a drug weaning program – Increases the exposure of a given workers’ compensation claim – Could lead to a large MSA amount and be an impediment to settlement
  • 20. HOW TO AVOID OPIOID PROBLEMS • Be sure to direct medical care for the first 28 days after an injury occurs – Could prevent the opioid cycle from starting • If/when opioids are being discussed as part of a treatment plan, consider a second opinion (e.g. IME) • Consider the use of a Nurse Case Manager (NCM) to oversee the treatment plan, once opioids are prescribed – Discuss alternatives to opioid treatment – Monitor the reports from the physicians in support of the continued use of opioids – Once opioids are being used, determine the appropriate plan to wean the injured worker off of the opioids • Contact an attorney to discuss the claim
  • 21. QUESTIONS? Renaldo P. DeFrank, Jr. LeVasseur & DeFrank, P.C. 24725 W. 12 Mile Rd., Ste 230 Southfield, MI 48034 Office: 248-356-8600 Cell: 248-207-6365 www.levasseurlaw.com rdefrank@levasseurlaw.com